JPWO2019147831A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019147831A5
JPWO2019147831A5 JP2020540397A JP2020540397A JPWO2019147831A5 JP WO2019147831 A5 JPWO2019147831 A5 JP WO2019147831A5 JP 2020540397 A JP2020540397 A JP 2020540397A JP 2020540397 A JP2020540397 A JP 2020540397A JP WO2019147831 A5 JPWO2019147831 A5 JP WO2019147831A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511058A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014978 external-priority patent/WO2019147831A1/en
Publication of JP2021511058A publication Critical patent/JP2021511058A/ja
Publication of JPWO2019147831A5 publication Critical patent/JPWO2019147831A5/ja
Priority to JP2023177262A priority Critical patent/JP2024009962A/ja
Pending legal-status Critical Current

Links

JP2020540397A 2018-01-26 2019-01-24 抗tmprss2抗体および抗原結合断片 Pending JP2021511058A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177262A JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622292P 2018-01-26 2018-01-26
US62/622,292 2018-01-26
PCT/US2019/014978 WO2019147831A1 (en) 2018-01-26 2019-01-24 Anti-tmprss2 antibodies and antigen-binding fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177262A Division JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Publications (2)

Publication Number Publication Date
JP2021511058A JP2021511058A (ja) 2021-05-06
JPWO2019147831A5 true JPWO2019147831A5 (sl) 2022-01-21

Family

ID=66102175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540397A Pending JP2021511058A (ja) 2018-01-26 2019-01-24 抗tmprss2抗体および抗原結合断片
JP2023177262A Pending JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177262A Pending JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Country Status (25)

Country Link
US (3) US10941213B2 (sl)
EP (1) EP3638698B1 (sl)
JP (2) JP2021511058A (sl)
KR (1) KR20200115576A (sl)
CN (1) CN111936517A (sl)
AU (1) AU2019211406A1 (sl)
BR (1) BR112020015112A2 (sl)
CA (1) CA3089377A1 (sl)
CY (1) CY1124182T1 (sl)
DK (1) DK3638698T3 (sl)
ES (1) ES2864529T3 (sl)
HR (1) HRP20210876T1 (sl)
HU (1) HUE054403T2 (sl)
IL (2) IL312961A (sl)
LT (1) LT3638698T (sl)
MA (1) MA46731B1 (sl)
MD (1) MD3638698T2 (sl)
MX (2) MX2020007888A (sl)
PL (1) PL3638698T3 (sl)
PT (1) PT3638698T (sl)
RS (1) RS61825B1 (sl)
SG (1) SG11202006898TA (sl)
SI (1) SI3638698T1 (sl)
WO (1) WO2019147831A1 (sl)
ZA (1) ZA202004494B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
KR20200115576A (ko) 2018-01-26 2020-10-07 리제너론 파아마슈티컬스, 인크. 항-tmprss2 항체 및 항원-결합 단편
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
CA3155630A1 (en) * 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
MX2022009476A (es) * 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
SG11202103404PA (en) 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
KR20230002612A (ko) * 2020-04-13 2023-01-05 매든 어드바이저스 엘엘씨 Ace2-표적화 조성물 및 covid-19의 치료 방법
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
CN116075725A (zh) 2020-04-17 2023-05-05 瑞泽恩制药公司 用于冠状病毒中和抗体的检测测定法
CN116096745A (zh) 2020-05-26 2023-05-09 瑞泽恩制药公司 抗sars-cov-2纤突糖蛋白抗体和抗原结合片段
WO2021247779A1 (en) 2020-06-03 2021-12-09 Regeneron Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES
US12097212B2 (en) 2020-06-08 2024-09-24 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
CN111986818A (zh) * 2020-08-21 2020-11-24 南通大学 一种基于tmprss2的新冠covid-19治疗药物筛选系统
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
WO2022115503A1 (en) 2020-11-25 2022-06-02 Dupont Nutrition Biosciences Aps Treatment and prevention of coronavirus infection
CN112538494A (zh) * 2020-12-08 2021-03-23 武汉华美生物工程有限公司 一种tmprss2突变体蛋白及其表达载体、表达工程菌和制备方法
WO2022133182A1 (en) * 2020-12-18 2022-06-23 Chan Zuckerberg Biohub, Inc. Method of treating coronavirus infection
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023199943A1 (ja) * 2022-04-12 2023-10-19 国立研究開発法人理化学研究所 コロナウイルス感染症を処置することに用いられる抗体
WO2023220712A1 (en) * 2022-05-13 2023-11-16 The Trustees Of Columbia University In The City Of New York Host proteases essential for parainfluenza spread in the human lung: potential targets for antiviral interventions
CN116003611B (zh) * 2022-08-17 2024-02-27 中南大学湘雅医院 抗tmprss2抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
CA2415923C (en) * 2000-07-12 2011-10-25 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8354508B2 (en) 2006-07-21 2013-01-15 Diadexus, Inc. PRO115 antibody compositions and methods of use
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
ES2707599T3 (es) * 2012-01-31 2019-04-04 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
MX2014012285A (es) 2012-04-16 2015-04-13 Regeneron Pharma Composicion farmaceutica que contiene un inhibidor de serina proteasa para tratar o prevenir infeccion por el virus de la influenza.
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
RU2749715C2 (ru) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
AU2018240303A1 (en) * 2017-03-22 2019-10-10 Children's Medical Center Corporation LRP1 binding agents and uses thereof
KR20200115576A (ko) 2018-01-26 2020-10-07 리제너론 파아마슈티컬스, 인크. 항-tmprss2 항체 및 항원-결합 단편

Similar Documents

Publication Publication Date Title
JPWO2019147831A5 (sl)
IL312961A (en) Antibodies against TMPRSS2 and antigen-binding fragments
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
JP2020532965A5 (sl)
JP2018527919A5 (sl)
JP2019526273A5 (sl)
JP2020501531A5 (sl)
JP2020528768A5 (sl)
JP2019533719A5 (sl)
JP2017529838A5 (sl)
JP2023178323A5 (sl)
JP2016531915A5 (sl)
RU2016129113A (ru) Антитела к pd-1 собак
JPWO2019129221A5 (sl)
US20220340673A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2010509931A5 (sl)
JP2024016024A5 (sl)
CN115397852A (zh) 工程化抗il-2抗体
JP2020533965A5 (sl)
JP2020502233A5 (sl)
JPWO2020011964A5 (sl)
TW202408586A (zh) 喜樹鹼類衍生物及配體-藥物偶聯物